Investor Presentation H1 2023
71
Investor presentation
First six months of 2023
The phase 3a OASIS 1 trial investigating oral semaglutide 50 mg
in people with overweight or obesity was completed in Q2 2023
OASIS 1 trial design
The trial included 660 patients with overweight or obesity
Oral semaglutide 50 mg
Objective
To investigate superiority of oral semaglutide 50 mg vs. placebo on
weight loss in people with overweight or obesity
R
1:1
Placebo oral
68 weeks
7 weeks
follow-up
Inclusion criteria
• BMI: ≥27 kg/m² with ≥ 1 weight-related comorbidity, or
• BMI ≥30 kg/m²
•
Weight-related comorbidities are hypertension, dyslipidaemia,
obstructive sleep apnoea and CVD
OASIS: Oral Semaglutide treatment effect In people with Obesity; CVD: Cardiovascular disease; BMI: Body Mass Index
Primary endpoint
•
Change in body weight from baseline (%)
Body weight reduction ≥ 5%
OASIS programme scope
Total of 1,000 patients across three trials: 1) A global (North
America and Europe), 2) Japanese and 3) Chinese trial
Novo NordiskⓇView entire presentation